

Blank cells = insufficient data or drug was not tested; H = HMC; U = UWMC.

^a *Citrobacter freundii*, *Enterobacter* spp., *Hafnia alvei*, *Morganella* spp., *Providencia* spp., *P. aeruginosa* and *Serratia* spp. have an inducible beta-lactamase. Resistance to penicillins and 3rd generation cephalosporins may arise on therapy.

^b Indicated in urinary tract infections only.

^c Chloramphenicol was tested at JIWMC with 48% of CE *S. maltophilia* isolates susceptible.

^d Colistin was tested at UWMC with 95% of CF *P. aeruginosa* isolates susceptible.

^f An insufficient number of isolates were recovered at IWMC in 2011 to be statistically significant. Data collected in 2010 may be found on the Healthlinks website at www.iwmc.nl.

All insufficient number of isolates were recovered at UWMC
<http://hsr.uw.edu/files/antibiograms/uw-som-2010-antibiogram>

⁹ Studies indicate that moxifloxacin has superior *in vitro* activity against *S. maltophilia* when compared to levofloxacin. No CLSI breakpoints are available; however EUCAST breakpoints for Enterobacteriaceae are <= 0.50 µg/ml, susceptible and >= 2.0 µg/ml, resistant.

Studies indicate that moxifloxacin has superior *In vitro* activity against *S. maltophilia* when compared to ciprofloxacin.

Due to a change in testing methodology at both HMC and UWMC, data for this antibiogram were compiled from organisms isolated April 2011 through December 2011.